Adaptive Biotechnologies Zukünftiges Wachstum
Future Kriterienprüfungen 5/6
Adaptive Biotechnologies wird ein jährliches Gewinn- und Umsatzwachstum von 75.5% bzw. 16.3% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 75.9% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 22.9% betragen.
Wichtige Informationen
75.5%
Wachstumsrate der Gewinne
75.92%
EPS-Wachstumsrate
| Life Sciences Gewinnwachstum | 18.8% |
| Wachstumsrate der Einnahmen | 16.3% |
| Zukünftige Eigenkapitalrendite | 22.90% |
| Analystenabdeckung | Good |
| Zuletzt aktualisiert | 18 Aug 2026 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Narrative-Update • Aug 27
ADPT: MRD Separation And Execution Trends Will Shape Future Cash Flows
Analysts have lifted the fair value estimate for Adaptive Biotechnologies to $28.00 from $24.91, reflecting updated views on revenue growth, margin potential, and future P/E assumptions following a series of higher Street price targets in the $20.00 to $28.00 range. Analyst Commentary Recent research updates on Adaptive Biotechnologies point to a cluster of higher price targets in the US$20 to US$28 range.
Narrative-Update • Aug 13
ADPT: MRD Volume Strength And Business Separation Will Shape Balanced Upside
Analysts have lifted the fair value estimate for Adaptive Biotechnologies from about $22.29 to roughly $25.07, citing a series of higher Street price targets following recent quarterly results, strong MRD volume growth, and raised guidance. Analyst Commentary Recent research updates on Adaptive Biotechnologies point to a cluster of higher price targets and generally constructive views on execution, particularly around the clonoSEQ MRD franchise and recent quarterly results.Seeking Alpha • Jul 31
Adaptive Biotechnologies: The MRD Separation Creates A Pure-Play Compounder
Summary Adaptive Biotechnologies (ADPT) is transitioning to a pure-play MRD diagnostics company, with the spin-off of Immune Medicine revealing strong underlying profitability. MRD revenue grew 49% year-over-year (excluding milestones), sequencing gross margins exceeded 70%, and adjusted EBITDA margin reached 14%, supporting a high-growth, high-quality earnings profile. Refinancing eliminated a 5% perpetual revenue burden, while the planned separation of Immune Medicine should clarify earnings and remove $6M in quarterly adjusted EBITDA losses. clonoSEQ adoption is accelerating, with blood-based testing at 51% of MRD volume, a 65% increase in community oncology, and a $245M pharma backlog, supporting a robust long-term growth runway. Read the full article on Seeking AlphaNarrative-Update • Jul 30
ADPT: MRD Focus And Volume Trends May Support Balanced Future Upside
Analysts have nudged their price targets higher on Adaptive Biotechnologies, with moves such as TD Cowen lifting its target to $25, Morgan Stanley to $20, and Guggenheim to $22. They cite model updates, large addressable markets, strong volume trends, and improving pricing as key supports for the revised valuation setup.Narrative-Update • Jul 15
ADPT: MRD Separation And Clinical Adoption Will Shape Future Cash Flows
The analyst price target for Adaptive Biotechnologies has been updated from $22.00 to about $24.91. Analysts cite large addressable markets, strong volume trends, improving pricing, and refreshed models ahead of upcoming earnings as key reasons for their revised view.Analyseartikel • Jun 20
Adaptive Biotechnologies (ADPT) Stock Could Be 13% Undervalued After Split Plan And $300 Million Notes
Why Adaptive Biotechnologies Just Drew Fresh Attention Adaptive Biotechnologies (ADPT) has moved into the spotlight after outlining plans to separate its Minimal Residual Disease and Immune Medicine businesses and completing a $300 million zero coupon convertible notes offering due 2031. Together, the planned business separation and new fixed income financing signal a meaningful shift in how Adaptive Biotechnologies funds its operations, manages capital and positions each segment for...Narrative-Update • Jun 17
ADPT: MRD Profitability And Business Separation Will Support Future Cash Flows
The analyst price target for Adaptive Biotechnologies has been adjusted to reflect a mix of recent Street research, including a $3 cut from one firm and a $2 increase from another. Analysts point to updated expectations for revenue growth, profit margins, and future P/E assumptions as key drivers of the revised outlook.Narrative-Update • Jun 02
ADPT: MRD Adoption And Margin Discipline Will Support Future Upside Potential
Analysts now see Adaptive Biotechnologies' fair value per share at $20.14, a level supported by updated assumptions for discount rate, revenue growth, profit margin and future P/E, alongside mixed recent Street research in which Morgan Stanley trimmed its price target by $3 while TD Cowen raised its target by $2. Analyst Commentary Recent research views on Adaptive Biotechnologies point to a mix of optimism and caution, which helps explain the updated fair value estimate of US$20.14 per share.Narrative-Update • May 17
ADPT: 2026 MRD Execution And Margin Discipline Will Support Future Upside Potential
Analysts now see Adaptive Biotechnologies' fair value edging from $20.57 to $20.14, reflecting mixed price target revisions. One firm cut its target by $3, while another raised its target by $2, as they update assumptions around growth, margins, the discount rate and future P/E expectations.Narrative-Update • May 01
ADPT: 2026 MRD Outlook And Margin Discipline Will Drive Future Upside Potential
The updated analyst price target for Adaptive Biotechnologies moves slightly lower to about $20.57 from $20.86. Analysts attribute this change to modest adjustments to fair value estimates, discount rate assumptions, and longer term profit margin and P/E expectations.Narrative-Update • Apr 16
ADPT: MRD Revenue Outlook And Refreshed Models Will Support Future Cash Flows
Narrative Update on Adaptive Biotechnologies The consensus analyst price target for Adaptive Biotechnologies has moved up by $1, reflecting updated analyst models that incorporate adjusted discount rates, refreshed revenue growth and profit margin assumptions, and a revised, still very large forward P/E framework. Analyst Commentary Recent Street research on Adaptive Biotechnologies centers on modestly higher price targets, with several bullish analysts revising their models at roughly the same time.Narrative-Update • Apr 02
ADPT: MRD 2026 Outlook And Discount Assumptions Will Support Future Upside Potential
Analysts have raised their price targets on Adaptive Biotechnologies by about $1, reflecting updated views on discount rates, growth, margins, and future P/E assumptions. These changes keep the stock's fair value estimate effectively unchanged at around $21.Narrative-Update • Mar 19
ADPT: MRD Outlook And Pfizer Agreements Will Support Future Cash Flows
Analysts have inched their average price targets on Adaptive Biotechnologies higher, often by about $1 increments. These changes reflect updated views that modestly adjust revenue growth, profit margin and future P/E assumptions while keeping the fair value estimate near $22.Narrative-Update • Mar 04
ADPT: MRD And Pfizer Agreements Will Support Future Cash Flow Upside
The analyst price target for Adaptive Biotechnologies has shifted from $21.00 to $22.00. Analysts point to updated assumptions around growth, profitability, and long-term P/E expectations following a series of recent target increases across the Street.Narrative-Update • Feb 18
ADPT: Pfizer Agreements And MRD Progress Will Support Future Upside Potential
Analysts have nudged their average price target for Adaptive Biotechnologies higher by about $1, reflecting updated fair value assumptions and slightly revised views on growth, margins and future P/E, in line with recent target increases from several research firms. Analyst Commentary Recent research updates cluster around modest target increases and a generally supportive view of Adaptive Biotechnologies, with most of the focus on refreshed fair value work rather than sweeping changes to the thesis.Narrative-Update • Feb 03
ADPT: Sector Tailwinds And Pfizer Partnerships Will Support Measured Future Upside
Analysts have nudged their price targets on Adaptive Biotechnologies slightly higher, with Street research pointing to target increases such as TD Cowen moving to $20 from $19. This contributes to a modest lift in our fair value estimate from $20.00 to about $20.14 as they highlight solid expected sector results and fundamentals.Narrative-Update • Jan 20
ADPT: Sector Tailwinds And Cancer Testing Leadership Will Support Future Upside
Narrative Update: Adaptive Biotechnologies The analyst price target for Adaptive Biotechnologies has moved from $19 to $20, reflecting updated views that incorporate recent Q4 preview work on diagnostics peers, expectations for solid sector results and 2026 outlooks, and the company’s latest Q3 report. Analyst Commentary Recent Street research around Adaptive Biotechnologies has focused on updated price targets that reflect fresh sector work and the company’s latest Q3 report.Narrative-Update • Jan 05
ADPT: MRD Platform And Pfizer Agreements Will Support Long-Term Cash Flow Upside
Analysts have lifted their price target on Adaptive Biotechnologies to $16 from $11, citing the recent Q3 report as the key driver behind this updated view. Analyst Commentary Bullish Takeaways Bullish analysts point to the new US$16 price target, up from US$11, as a sign that expectations for execution and risk reward have shifted in a more constructive direction after the recent Q3 report.Narrative-Update • Dec 15
ADPT: MRD Leadership Will Drive Long-Term Cash Flow Upside
Analysts have raised their fair value estimate for Adaptive Biotechnologies from approximately $15 to $21 per share. They cite higher long term profit margin expectations and confidence in the company’s leadership in minimal residual disease cancer testing, even with moderating revenue growth assumptions and a higher discount rate.Narrative-Update • Nov 30
ADPT: Future Revenue Will Be Sustained By Leadership In Cancer Testing
Analysts have raised their fair value estimate for Adaptive Biotechnologies to $19.57 from $19.14. They cite increased confidence in the company's sustained revenue growth and leadership position in cancer testing.Narrative-Update • Nov 16
ADPT: Future Revenue Will Be Driven By Market Expansion In Blood Cancer Testing
Analysts have raised their price target for Adaptive Biotechnologies by $2.00 to $19.14, citing the company's leadership in minimal residual disease testing, as well as expectations for sustained revenue growth and improved margins. Analyst Commentary Recent analyst discussions reveal diverse perspectives on Adaptive Biotechnologies' position in the market and future prospects.Narrative-Update • Nov 01
ADPT: Leadership In Cancer Testing Will Drive Market Expansion And Execution Risks
Analysts have increased their price target for Adaptive Biotechnologies from $16.00 to $17.14 per share. They cite continuing leadership in cancer testing and expectations for robust revenue growth, driven by market expansion and operational improvements.Narrative-Update • Oct 18
EMR Integration And Partnerships Will Reshape Clinical Diagnostics
Analysts have raised their price target for Adaptive Biotechnologies from $14.86 to $16.00. They cite the company’s strong positioning in cancer testing and sustained revenue growth potential.Analyseartikel • Oct 16
Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) 31% Jump Shows Its Popularity With Investors
Adaptive Biotechnologies Corporation ( NASDAQ:ADPT ) shares have continued their recent momentum with a 31% gain in the...Narrative-Update • Oct 04
EMR Integration And Partnerships Will Reshape Clinical Diagnostics
Analysts have increased their price target for Adaptive Biotechnologies from $14 to approximately $14.86 per share. They cite ongoing revenue growth momentum and strengthening leadership in the cancer diagnostics market as key drivers of the upward revision.Analyseartikel • Sep 24
Is Adaptive Biotechnologies (NASDAQ:ADPT) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analyseartikel • Aug 29
Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) P/S Is Still On The Mark Following 28% Share Price Bounce
Despite an already strong run, Adaptive Biotechnologies Corporation ( NASDAQ:ADPT ) shares have been powering on, with...Narrative-Update • Aug 07
EMR Integration And Partnerships Will Reshape Clinical Diagnostics
Despite a modest decline in consensus revenue growth forecasts and a slight increase in the discount rate, the consensus analyst price target for Adaptive Biotechnologies has been raised from $11.86 to $13.29. What's in the News Raised full year 2025 MRD business revenue guidance to $190–200 million from the prior $180–190 million range; no revenue guidance for Immune Medicine.Analyseartikel • May 31
Market Participants Recognise Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Revenues Pushing Shares 29% Higher
Adaptive Biotechnologies Corporation ( NASDAQ:ADPT ) shareholders would be excited to see that the share price has had...Analyseartikel • May 07
Is Adaptive Biotechnologies (NASDAQ:ADPT) Using Debt In A Risky Way?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analyseartikel • Apr 10
Why Investors Shouldn't Be Surprised By Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) 26% Share Price Surge
The Adaptive Biotechnologies Corporation ( NASDAQ:ADPT ) share price has done very well over the last month, posting an...
Neues Narrative • Mar 25
ClonoSEQ And NovaSeq X Will Transform Clinical Testing Pipelines
Strategic partnerships and initiatives to raise test prices and efficiency are expected to drive substantial revenue and margin growth.Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2028 | 439 | 3 | 92 | 41 | 5 |
| 12/31/2027 | 359 | -28 | 46 | 11 | 8 |
| 12/31/2026 | 293 | -86 | -5 | -68 | 8 |
| 6/30/2026 | 308 | -64 | -24 | -21 | N/A |
| 3/31/2026 | 295 | -50 | -30 | -27 | N/A |
| 12/31/2025 | 277 | -59 | -49 | -46 | N/A |
| 9/30/2025 | 253 | -80 | -63 | -61 | N/A |
| 6/30/2025 | 205 | -121 | -83 | -80 | N/A |
| 3/31/2025 | 190 | -142 | -89 | -85 | N/A |
| 12/31/2024 | 179 | -159 | -99 | -95 | N/A |
| 9/30/2024 | 177 | -195 | -115 | -110 | N/A |
| 6/30/2024 | 169 | -213 | -137 | -129 | N/A |
| 3/31/2024 | 175 | -215 | -145 | -136 | N/A |
| 12/31/2023 | 170 | -225 | -167 | -156 | N/A |
| 9/30/2023 | 180 | -196 | -171 | -159 | N/A |
| 6/30/2023 | 190 | -191 | -170 | -155 | N/A |
| 3/31/2023 | 184 | -195 | -195 | -179 | N/A |
| 12/31/2022 | 185 | -200 | -200 | -184 | N/A |
| 9/30/2022 | 168 | -221 | -231 | -208 | N/A |
| 6/30/2022 | 160 | -232 | -241 | -209 | N/A |
| 3/31/2022 | 155 | -229 | -248 | -199 | N/A |
| 12/31/2021 | 154 | -207 | -254 | -193 | N/A |
| 9/30/2021 | 147 | -190 | -241 | -179 | N/A |
| 6/30/2021 | 133 | -171 | -234 | -182 | N/A |
| 3/31/2021 | 116 | -155 | -208 | -176 | N/A |
| 12/31/2020 | 98 | -146 | -168 | -150 | N/A |
| 9/30/2020 | 92 | -122 | -148 | -137 | N/A |
| 6/30/2020 | 92 | -99 | -131 | -120 | N/A |
| 3/31/2020 | 93 | -82 | N/A | -105 | N/A |
| 12/31/2019 | 85 | -70 | N/A | 205 | N/A |
| 9/30/2019 | 78 | -62 | N/A | 227 | N/A |
| 6/30/2019 | 69 | -56 | N/A | 245 | N/A |
| 3/31/2019 | 59 | -53 | N/A | 252 | N/A |
| 12/31/2018 | 56 | -46 | N/A | -32 | N/A |
| 12/31/2017 | 38 | -43 | N/A | -35 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: ADPT wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (3.7%).
Ertrag vs. Markt: ADPT wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.
Hohe Wachstumserträge: ADPT wird voraussichtlich in den nächsten 3 Jahren rentabel werden.
Einnahmen vs. Markt: ADPTDie Einnahmen des Unternehmens (16.3% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (13.5% pro Jahr).
Hohe Wachstumseinnahmen: ADPTDie Einnahmen des Unternehmens (16.3% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: ADPTDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich hoch sein (22.9%)
Wachstumsunternehmen entdecken
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/09/09 20:07 |
| Aktienkurs zum Tagesende | 2026/09/09 00:00 |
| Gewinne | 2026/06/30 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.
Erfahren Sie mehr über das , das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Adaptive Biotechnologies Corporation wird von 15 Analysten beobachtet. 8 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Derik de Bruin | BofA Global Research |
| Mark Massaro | BTIG |
| William Bonello | Craig-Hallum Capital Group LLC |